Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate

Clinical Cancer Research

Volumn 17, Issue 24, 2011, Pages 7634-7644

  Liu, Glenn ^a,b,c   Jeraj, Robert ^a,b,c   Vanderhoek, Matt ^c   Perlman, Scott ^a,b   Kolesar, Jill ^a,b   Harrison, Michael ^a,b,c   Simoncic, Urban ^c   Eickhoff, Jens ^a,b   Carmichael, Lakeesha ^a,b   Chao, Bo ^c   Marnocha, Rebecca ^a,b   Ivy, Percy ^d   Wilding, George ^a,c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; INTERLEUKIN 2; SUNITINIB; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANALYTICAL PARAMETERS; ARTICLE; CARCINOSARCOMA; CELL PROLIFERATION; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FEMALE; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SARCOMA; SOLID TUMOR; STANDARDIZED UPTAKE VALUE; THYMUS CANCER; TREATMENT RESPONSE; UTERUS CARCINOSARCOMA;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; INDOLES; KIDNEY; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PYRROLES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84055222066     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1677     Document Type: Article

References (45)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-24. (Pubitemid 37433402)
3. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50. (Pubitemid 32119100)
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: 2335-42. (Pubitemid 38702844)
5. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44. (Pubitemid 46733080)
6. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:1250-34.
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. (Pubitemid 46089672)
9. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-8.
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
11. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-8.
12. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38. (Pubitemid 44528723)
13. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010;70:1053-62.
14. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008;61:515-24. (Pubitemid 350275988)
15. Heng DY, Rini BI, Garcia J, Wood L, Bukowski RM. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer 2007;5: 446-51. (Pubitemid 351219698)
16. Calvo OF, Vazquez DD, Lopez MR, Aparicio LM. Renal cell carcinoma: complete response. Anticancer Drugs 2010;21 Suppl 1:S17-8.
17. Garcia-Campelo R, Quindos M, Vazquez DD, Lopez MR, Carral A, Calvo OF, et al. Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma. Anticancer Drugs 2010;21 Suppl 1:S13-5.
18. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34. (Pubitemid 36910021)
19. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536-41. (Pubitemid 350035309)
20. Liu G, Jeraj R, Perlman S, Vanderhoek M, Kolesar J, Eickhoff J, et al. Pharmacodynamic study of FLT-PET imaging in patients treated with sunitinib. J Clin Oncol 2008;26:abstr 3515.
21. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474-83.
22. Toyohara J, Waki A, Takamatsu S, Yonekura Y, Magata Y, Fujibayashi Y. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002;29:281-7. (Pubitemid 34258548)
23. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7. (Pubitemid 34988769)
24. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 1995;35:69-89.
25. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 30-deoxy-30-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer research 2003;63:3791-8. (Pubitemid 36793068)
26. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003;44: 2027-32. (Pubitemid 40022149)
27. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, et al. In vivo validation of 30deoxy-30-[(18)F]fluorothymidine ([(18) F]FLT) as a proliferation imaging tracer in humans: correlation of [(18) F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-23. (Pubitemid 35340704)
28. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003;44:1426-31. (Pubitemid 39663355)
29. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005;43:153-67. (Pubitemid 40326566)
30. Muzi M, Vesselle H, Grierson JR, Mankoff DA, Schmidt RA, Peterson L, et al. Kinetic analysis of 30-deoxy-30-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005; 46:274-82. (Pubitemid 43073435)
31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
32. de Bruijn P, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA, Loos WJ. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal 2010;51:934-41.
33. Thie JA, Hubner KF, Smith GT. The diagnostic utility of the lognormal behavior of PET standardized uptake values in tumors. J Nucl Med 2000;41:1664-72.
34. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30.
35. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:1835-42.
36. Kindler HL, Ioka T, Richel DJ, Bennouna J, Letourneau R, Okusaka T, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011;12: 256-62.
37. Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M, et al. Final results from a multicenter, randomized, double-blind, phase 3 study of sunitinib in metastatic colorectal cancer patients receiving irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) as first line treatment. 12th World Congress on Gastrointestinal Cancer. Barcelona, Spain: European Society of Medical Oncology, 2010. Abstract nr O-0026.
38. Teicher BA. A systems approach to cancer therapy. (Antioncogenics+ standard cytotoxics->mechanism(s) of interaction). Cancer Metastasis Rev 1996;15:247-72.
39. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9. (Pubitemid 32937367)
40. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
41. Hillman GG, Singh-Gupta V, Al-Bashir AK, Zhang H, Yunker CK, Patel AD, et al. Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors. Transl Oncol 2010;3:293-306.
42. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007; 5:32.
43. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1432-9.
44. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009;15:6277-83.
45. Jeraj R, Liu G, Simoncic U, Vanderhoek M, Perlman SB, Alberti D, et al. Concurrent assessment of vasculature and proliferative pharmacodynamics in patients treated with VEGFR TKI. J Clin Oncol 2010;28:abstr 3050.